One of the most common conversations I have in consultation goes something like this: a patient comes in, they've had filler before, they're happy with the results — but they're also a little uncertain about doing it again. Not because they didn't like what they saw, but because they're not sure what exactly filler is doing inside their skin. Is it just sitting there? Will it stretch things out? And when it dissolves, does everything go back to zero?

These are reasonable questions, and they deserve a rigorous answer. Not reassurance — actual biology. So when a 2025 prospective clinical study examined what cross-linked hyaluronic acid filler does to facial tissue over twelve months, I paid close attention. What it showed is worth communicating clearly to every patient who is considering treatment.

What HA Filler Actually Does to the Dermis The mechanism most people understand — and the one clinics most often describe — is volumisation. You inject hyaluronic acid into the dermis or subdermis, it occupies space, and the face looks fuller. That's accurate. But it describes only the first chapter of what's happening.

The more complete picture begins with the physical properties of HA when it's placed in tissue. Hyaluronic acid is a large, hydrophilic molecule — it's capable of holding approximately 1,000 times its own weight in water. When it's introduced into the extracellular matrix, it draws in moisture and creates a hydrated, gel-like environment. But beyond hydration, the physical presence of the filler does something structurally important: it stretches the surrounding fibroblasts.

Fibroblasts are the cells responsible for synthesising collagen and elastin — the structural proteins that give skin its firmness and resilience. When they're mechanically stretched by the presence of injected filler, they respond. Specifically, that mechanical stimulus triggers the release of transforming growth factor-beta 1 (TGF-β1) and TGF-β3. These are potent signalling molecules that activate collagen-producing pathways. The filler, in other words, doesn't just fill a space — it creates a biological environment that prompts the skin to rebuild its own architecture.

The Timeline That Most Patients Don't Know About In the 2025 prospective clinical evaluation, researchers followed patients treated with 30mg cross-linked sodium hyaluronate over a twelve-month period across multiple facial indications. What emerged was a clear, phased timeline of improvement that most patients — and perhaps some practitioners — don't fully anticipate. Immediately post-injection, the visible changes are what you'd expect: volume restored, skin surface smoothed, and improved hydration as HA begins drawing water into the tissue. This is the result most patients are mentally prepared for.

At approximately six months, something more interesting happens: collagen production peaks. The fibroblast stimulation initiated by the mechanical stretch of the filler has been running in the background since treatment, and by this point it has produced measurable new collagen. This is why patients so frequently return at their six-month follow-up and say the results look better than they did at two weeks. They are not imagining this. At that point, they are seeing a composite result — the filler itself, and the collagen it has stimulated.

By twelve months, tissue integration reaches maturity. The volumisation is at its peak, even as the HA itself has begun to partially metabolise. The structural improvement persists because it's no longer dependent entirely on the presence of the filler — it's now supported by the tissue the filler helped rebuild.

What the Numbers Show The patient outcomes from this study are worth stating directly. At twelve months, 36.88% of patients were rated "very much improved" and 48.36% were rated "much improved" on the Full Face Global Aesthetic Assessment Scale — 85% in meaningful improvement territory. Only 1.64% showed no change, and no deterioration was recorded in any patient. These results were statistically significant (p < 0.001). What makes these numbers particularly telling is that they improve over the course of the study period. The results at twelve months are better than those at six months, and those at six months are better than those at baseline. This compounding trajectory is exactly what the biology predicts, and it's exactly what we should be telling patients to expect.

What This Means in Practice The clinical implications of this are meaningful in two directions — for how we treat, and for how we talk about treatment.

On the treatment side, it reinforces the value of a conservative, cumulative approach. If collagen remodelling is contributing to results over twelve months, then the decision about whether to retreat at six months should account for this trajectory. Adding more volume to a face that is still actively improving biologically is a different clinical decision than treating a face where the previous product has fully resolved. This is why thorough treatment history, technique precision, and product selection all matter as much as they do. On the communication side, it gives us something genuinely positive and scientifically grounded to share with patients who are uncertain. The concern that filler is purely synthetic, that it replaces rather than restores, that when it goes everything goes with it — none of that is consistent with what the evidence shows. Filler, placed correctly, initiates a regenerative process. The improvement that accrues over months is real, measurable, and partly biological in origin.

I would rather a patient understand this and make a decision with that context than proceed — or decline — based on an incomplete picture.

The Honest Note None of this is an argument that filler is for everyone, or that the decision is uncomplicated. Individual responses vary. Technique and product selection matter enormously. And as with any injectable treatment, the experience and judgment of the practitioner shapes the outcome more than any single variable in the literature. What the evidence offers is a foundation for an honest, informed conversation — not a promise. But when a patient asks me whether filler is "just temporary," I can now tell them, with good evidence behind me: not exactly. What it leaves behind, when done well, is partly yours.

📌 Prospective Clinical Evaluation of Cross-Linked Hyaluronic Acid Dermal Filler (30 mg) for Facial Rejuvenation. (2025). Plastic and Reconstructive Surgery – Global Open. https://doi.org/10.1097/GOX.0000000000005934